Eligo raises EUR 2M for CRISPR-based antibiotics

Microbiome antibiotics play Eligo Bioscience S.A.S. (Paris, France) raised EUR 2 million ($2.2 million) in a seed financing from sole investor Seventure Partners. The spinout from Massachusetts Institute of Technology and Rockefeller University is developing Eligobiotics, which contain bacteria-specific, RNA-guided CRISPR nucleases delivered via capsids from bacteriophages to selectively eliminate targeted bacteria while leaving beneficial bacteria unaffected (see SciBX: Science-Business eXchange, Oct. 23, 2014).

The company has two preclinical programs against undisclosed targets in the gut and skin microbiomes. ...